Search clinical trials for: AL3818

Total 65 results

Advenchen Laboratories, LLC

Available

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Gynecologic Cancer | Sarcoma,Soft Tissue
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
First Affiliated Hospital Xi'an Jiaotong University
Tang-Du Hospital; Yan'an University Affiliated Hospital

Unknown

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Non-squamous NSCLC

China
Shanghai Zhongshan Hospital

Withdrawn

Adjuvant Therapy With Anlotinib for HCC

Hepatocellular Carcinoma

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing... and other collaborators

Unknown

Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy

Soft Tissue Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (ALTER0703)

Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (ALTER0303)

Non-small Cell Lung Cancer

China
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
The First Affiliated Hospital of Xinxiang Medical...

Recruiting

Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (AP)

Lung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung Neoplasm

China
Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Unknown

Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810

Advanced Solid Tumor | Advanced/Metastatic Colorectal Cancer

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Huashan Hospital

Active, not recruiting

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

Malignant Glioma

China
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Advenchen Laboratories, LLC

Active, not recruiting

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (APROMISS)

Leiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue Sarcoma

United States, United Kingdom, Spain, China, Italy
Ruijin Hospital

Recruiting

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Soft Tissue Sarcoma | Radiotherapy | Anlotinib | High Risk of Recurrence

China
Advenchen Laboratories, LLC

Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (AL3818)

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

Stage III Non-small-cell Lung Cancer

China
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Fatigue | NSCLC | Cachexia

Canada, Australia, Russian Federation, Georgia, Serbia, India, New Zealand, Poland, Romania
Shi Yuankai

Recruiting

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Head and Neck Squamous Cell Carcinoma

China
Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Completed

Study of the AL3810 in the Treatment of Advanced Solid Tumor

Advanced Solid Tumors

China
Allergan

Terminated

Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Cystitis, Interstitial

United States
CSL Behring

Terminated

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Oral Mucositis

United States, Canada, Australia, Germany, Italy, Austria
Allergan

Terminated

Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

Fibromyalgia

Switzerland, United States, United Kingdom
Sun Yat-sen University

Not yet recruiting

Peramprizumab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Allergan

Terminated

Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

Irritable Bowel Syndrome

United States
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Allergan

Completed

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Diabetic Neuropathy, Painful

United States
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
CSL Behring

Terminated

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) (ALD518-010)

Acute GvHD

United States
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis (ALD518-003)

Arthritis, Rheumatoid

Russian Federation, Serbia, Georgia, Canada, India, Poland
Peking University People's Hospital

Unknown

Anlotinib and Irinotecan for Ewing Sarcoma

Ewing's Tumor Metastatic

China
Sarcoma Oncology Research Center, LLC
Advenchen Laboratories, LLC

Active, not recruiting

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Non Small Cell Lung Cancer | Solid Tumor, Adult

United States
GlaxoSmithKline

Terminated

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

HIV Infection

United States, Germany, Belgium, Canada, Denmark
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

Small Cell Lung Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Breast Neoplasm Female

China
Henan Cancer Hospital

Recruiting

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Breast Cancer

China
Tianjin Medical University Second Hospital

Not yet recruiting

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Urogenital Neoplasms | Urothelial Carcinoma | Antineoplastic Agents | Gemcitabine | Cisplatin | Anlotinib | Carboplatin

China
Sichuan Provincial People's Hospital

Recruiting

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (NeoATCT)

Triple-negative Breast Cancer

China
Zhejiang Cancer Hospital

Unknown

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

Prostate Adenocarcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
Haihe Biopharma Co., Ltd.

Unknown

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Extensive-stage Small Cell Lung Cancer

China
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Stage IV Prostate Adenocarcinoma AJCC v7 | PSA Level Greater Than Two

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States, Canada
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (TARGET)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States

Search clinical trials for: AL3818

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations